SOPHiA GENETICS Provides Update In Co’s DEEP-Lung-IV Multimodal Clinical Study At ASCO 2022

https://www.sophiagenetics.com/press-releases/sophia-genetics-provides-an-update-on-its-deep-lung-iv-multimodal-clinical-study-at-asco-2022/

byBenzinga Newsdesk

June 6, 2022

1 minute read

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site For INDP-D101 Phase 1 Open-Label Trial of Decoy20 In Patients With Advanced Solid Tumors

By Benzinga Newsdesk

Today, 5:02 AM

The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK),

INDP

Recap: WisdomTree Inv Q2 Earnings

By Benzinga Insights

Today, 5:02 AM

WisdomTree Inv (NASDAQ:WETF) reported its Q2 earnings results on Friday, July 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings WisdomTree Inv reported in-line EPS of $0.07 versus an estimate of $0.07.

WETF